Impact of Mercaptopurine Metabolites on Disease Outcome in the AIEOP-BFM ALL 2009 Protocol for Acute Lymphoblastic Leukemia.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
17
02
2023
accepted:
01
08
2023
pubmed:
8
8
2023
medline:
8
8
2023
entrez:
8
8
2023
Statut:
ppublish
Résumé
In the maintenance phase of Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)- Berlin-Frankfurt-Muenster (BFM) acute lymphoblastic leukemia (ALL) 2009 protocol, mercaptopurine (MP) is given at the planned dose of 50 mg/m
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1082-1092Informations de copyright
© 2023 The Authors. Clinical Pharmacology & Therapeutics © 2023 American Society for Clinical Pharmacology and Therapeutics.
Références
Pui, C.H. Precision medicine in acute lymphoblastic leukemia. Front. Med. 14, 689-700 (2020).
Cooper, S.L. & Brown, P.A. Treatment of pediatric acute lymphoblastic leukemia. Pediatr. Clin. North Am. 62, 61-73 (2015).
Toyoda, Y. et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J. Clin. Oncol. 18, 1508-1516 (2000).
Schmiegelow, K. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 8, 301-312 (1991).
Riehm, H. et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol. Blood Transfus. 33, 439-450 (1990).
Schmiegelow, K., Nielsen, S.N., Frandsen, T.L. & Nersting, J. Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J. Pediatr. Hematol. Oncol. 36, 503-517 (2014).
Mikkelsen, T.S. et al. PharmGKB summary: methotrexate pathway. Pharmacogenet. Genomics 21, 679-686 (2011).
Zaza, G. et al. Thiopurine pathway. Pharmacogenet. Genomics 20, 573-574 (2010).
Cara, C.J. et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med. Sci. Monit. 10, RA247-54 (2004).
Shin, J.Y., Wey, M., Umutesi, H.G., Sun, X., Simecka, J. & Heo, J. Thiopurine prodrugs mediate immunosuppressive effects by interfering with Rac1 protein function. J. Biol. Chem. 291, 13699-13714 (2016).
Karim, H., Ghalali, A., Lafolie, P., Vitols, S. & Fotoohi, A.K. Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells. Biochem. Biophys. Res. Commun. 437, 280-286 (2013).
Franca, R., Braidotti, S., Stocco, G. & Decorti, G. Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies. Expert Opin. Drug Metab. Toxicol. 17, 1187-1198 (2021).
Moriyama, T. et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat. Genet. 48, 367-373 (2016).
Relling, M.V. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin. Pharmacol. Ther. 105, 1095-1105 (2018).
Franca, R. et al. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol. Pharmacogenomics J. 17, 4-10 (2017).
Franca, R. et al. PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients. Pharmacogenomics J. 20, 415-425 (2020).
Dumont, V. & Lehtonen, S. PACSIN proteins in vivo: roles in development and physiology. Acta Physiol (Oxf) 234, e13783 (2022).
Zudeh, G. et al. PACSIN2 as a modulator of autophagy and mercaptopurine cytotoxicity: mechanisms in lymphoid and intestinal cells. Life Sci Alliance 6, e202201610 (2023).
Zimdahl Kahlin, A., Helander, S., Wennerstrand, P., Vikingsson, S., Mårtensson, L.G. & Appell, M.L. Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism. Basic Clin. Pharmacol. Toxicol. 128, 52-65 (2021).
Wennerstrand, P., Mårtensson, L.G., Söderhäll, S., Zimdahl, A. & Appell, M.L. Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia. Eur. J. Clin. Pharmacol. 69, 1641-1649 (2013).
Zaza, G. et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 106, 1778-1785 (2005).
Whiley, A.C., Price, V. & MacDonald, T. An exploration of mercaptopurine/methotrexate tolerance during maintenance therapy in children with acute lymphoblastic leukemia. J. Oncol. Pharm. Pract. 27, 1631-1636 (2021).
Schmiegelow, K. et al. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? Pediatr Blood Cancer 63, 2104-2111 (2016).
Tulstrup, M. et al. Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: a NOPHO randomized controlled trial. Eur. J. Haematol. 100, 53-60 (2018).
Frandsen, T.L. et al. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. Br. J. Haematol. 155, 244-247 (2011).
Bajaj, A.O. et al. LC-MS/MS method for measurement of thiopurine nucleotides (TN) in erythrocytes and association of TN concentrations with TPMT enzyme activity. Front. Pharmacol. 13, 836812 (2022).
Lennard, L., Lilleyman, J.S., Van Loon, J. & Weinshilboum, R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336, 225-229 (1990).
Schmiegelow, K. et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J. Clin. Oncol. 13, 345-351 (1995).
Bhatia, S. et al. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a Children's oncology group study. JAMA Oncol. 1, 287-295 (2015).
Lennard, L. & Lilleyman, J.S. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J. Clin. Oncol. 7, 1816-1823 (1989).
Boissel, N. & Baruchel, A. Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children? Blood 132, 351-361 (2018).
Hunger, S.P. & Raetz, E.A. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood 136, 1803-1812 (2020).
Bonifant, C.L. & Tasian, S.K. The future of cellular immunotherapy for childhood leukemia. Curr. Opin. Pediatr. 32, 13-25 (2020).
Montecchini, O. et al. A novel ELISA-based peptide biosensor assay for screening ABL1 activity. Front. Pharmacol. 12, 749361 (2021).
Franca, R. et al. Targeting kinase-activating genetic lesions to improve therapy of pediatric acute lymphoblastic leukemia. Curr. Med. Chem. 25, 2811-2825 (2018).
Franca, R., Favretto, D., Granzotto, M., Decorti, G., Rabusin, M. & Stocco, G. Epratuzumab and blinatumomab as therapeutic antibodies for treatment of pediatric acute lymphoblastic leukemia: current status and future perspectives. Curr. Med. Chem. 24, 1050-1065 (2017).
Rizzari, C. et al. Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica 104, 1812-1821 (2019).
Schmiegelow, K., Björk, O., Glomstein, A. et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 21, 1332-1339 (2003).
Relling, M.V., Hancock, M.L., Boyett, J.M., Pui, C.H. & Evans, W.E. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93, 2817-2823 (1999).
Lilleyman, J.S. & Lennard, L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343, 1188-1190 (1994).
Landier, W. et al. Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group Study. Blood 129, 1919-1926 (2017).
Landier, W. et al. Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group Study AALL03N1. J. Clin. Oncol. 35, 1730-1736 (2017).
Nielsen, S.N. et al. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Lancet Oncol 18, 515-524 (2017).
Adam de Beaumais, T. et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol 71, 575-584 (2011).
Choi, R. et al. Quantification of thioguanine in DNA using liquid chromatography-tandem mass spectrometry for routine thiopurine drug monitoring in patients with pediatric acute lymphoblastic leukemia. Ann Lab Med 41, 145-154 (2021).
Wu, Y.P. et al. Adherence to oral medications during maintenance therapy among children and adolescents with acute lymphoblastic leukemia: a medication refill analysis. J. Pediatr. Oncol. Nurs. 35, 86-93 (2018).
Rudin, S., Marable, M. & Huang, R.S. The promise of pharmacogenomics in reducing toxicity during acute lymphoblastic leukemia maintenance treatment. Genomics Proteomics Bioinformatics 15, 82-93 (2017).
Franca, R., Zudeh, G., Lucafò, M., Rabusin, M., Decorti, G. & Stocco, G. Genome wide association studies for treatment-related adverse effects of pediatric acute lymphoblastic leukemia. Wiley Interdiscip. Rev. Syst. Biol. Med. 13, e1509 (2020).
Stocco, G. et al. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum. Mol. Genet. 21, 4793-4804 (2012).
de Kreuk, B.J. et al. The F-BAR domain protein PACSIN2 associates with Rac1 and regulates cell spreading and migration. J. Cell Sci. 124(Pt 14), 2375-2388 (2011).
Sanderlin, A.G., Vondrak, C., Scricco, A.J., Fedrigo, I., Ahyong, V. & Lamason, R.L. RNAi screen reveals a role for PACSIN2 and caveolins during bacterial cell-to-cell spread. Mol Biol Cell 30, 2124-2133 (2019).
Nguyen, L.P., Tran, S.C., Suetsugu, S., Lim, Y.S. & Hwang, S.B. PACSIN2 interacts with nonstructural protein 5A and regulates hepatitis C virus assembly. J Virol 94, e01531-19 (2020).
Popov, S., Popova, E., Inoue, M., Wu, Y. & Göttlinger, H. HIV-1 gag recruits PACSIN2 to promote virus spreading. Proc Natl Acad Sci USA 115, 7093-7098 (2018).
Shipkova, M., Lorenz, K., Oellerich, M., Wieland, E. & von Ahsen, N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin. Chem. 52, 240-247 (2006).
Lee, Y., Jang, E.J., Yoon, H.Y., Yee, J. & Gwak, H.S. Effect of ITPA polymorphism on adverse drug reactions of 6-mercaptopurine in pediatric patients with acute lymphoblastic leukemia: a systematic review and meta-analysis. Pharmaceuticals (Basel) 15, 416 (2022).
Barba, E., Kontou, P.I., Michalopoulos, I., Bagos, P.G. & Braliou, G.G. Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis. Pharmacogenomics J. 22, 39-54 (2022).